Defence Therapeutics Inc.

Recent News

  • Defence Therapeutics Accum(TM) Variants in Vitro Study Increases the Potency of T-Deruxtecan ADC by 5-Fold on Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - October 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu® (fam-trastuzumab-deruxtecan-nxki) ADC owned by AstraZeneca and Daiichi Sankyo. Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic. The 5 selected Accum-T-deruxtecan increases the potency...

    2021-10-13 3:15 AM EDT
  • Defence Therapeutics Prepares for Phase I Trial to Test Its DC Cancer Vaccine, AccuVAC-D002, Against Melanoma

    Vancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is finalizing all required steps in preparation to a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002.Defence has successfully exploited the use of its AccumTM technology platform to develop a large pipeline of products in immune-oncology and...

    2021-10-06 3:15 AM EDT
  • Defence Therapeutics to Finalize Its Objectives to Initiate a Phase I Trial Against Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - September 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology Company working on cancer therapeutics and infectious diseases vaccines, is pleased to announce that it will be conducting a series of final studies to complete all requirement needed to initiate a Phase I trial for one of its leading AccuTOX candidate against breast cancer. The AccumTM technology platform was initially designed to enhance...

    2021-09-29 3:15 AM EDT
  • Defence Therapeutics Successfully Engineered and Tested a Novel Intranasal COVID-19 Vaccine Formulation in Animals

    Vancouver, British Columbia--(Newsfile Corp. - September 20, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the development of a "non-injectable" second generation COVID vaccine, AccuVAC-IN002, for intranasal delivery. Vaccination against SARS2-COVID was initially efficient at slowing down viral spreading across the globe. However, the arrival of new and more infectious strains is challenging to current...

    2021-09-20 3:15 AM EDT
  • Defence Therapeutics Success in Testing Its COVID-19 AccuVAC-PT001 Vaccine in a Non-Rodent Model

    Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is pleased to announce the completion of a non-GLP study on rabbits demonstrating a potent humoral response with titer reaching 1:43 000 000 per average without any signs of toxicity. Defence has previously developed and tested its AccuVAC-PT001 vaccine in mice. This vaccine is highly...

    2021-09-14 3:15 AM EDT
  • Defence Therapeutics Development Program to Engineer a New HPV Vaccine Initiated

    Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines, is pleased to announce the establishment of a high priority program to develop a novel HPV-targeting vaccine for cervical cancer with it's AccumTM technology. Currently there are more than 40 types of HPV strains capable...

    2021-09-07 3:15 AM EDT
  • Defence Therapeutics Files Acid-Based Hydrogels USA Provisional Patent Application

    Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines is pleased to announce the expansion of its patent portfolio through the filing of its AccumTM technology-based USA Provisional Patent Application named "Steroid Acid-Based Hydrogels". Hydrogels are cross-linked polymer networks that can swell and retain...

    2021-08-31 3:15 AM EDT
  • Defence Therapeutics Selects the Best Eight Accum(TM) Variants to Optimize Its ADC Therapeutic

    Vancouver, British Columbia--(Newsfile Corp. - August 18, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce, that after a detailed and rigorous selection process, very strong and promising results of its bests AccumTM variants has been identified. Defence's has tested 43 AccumTM variants conjugated to T-DM1 with a low conjugation ratio (1-4 AccumTM per T-DM1) in order to select the best ones to pursue our selection of the optimized Accum-T-DM1 conjugate based on in...

    2021-08-18 3:15 AM EDT